Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Propantheline bromide 15mg tablets
0102000Y0AAAFAF
|
Propantheline bromide | Propantheline bromide | Gastro-Intestinal System | 16,876 |
|
Pro-Banthine 15mg tablets
0102000Y0BBAAAF
|
Pro-Banthine | Propantheline bromide | Gastro-Intestinal System | 1,310 |
|
Propantheline bromide 10mg/5ml oral solution
0102000Y0AAAUAU
|
Propantheline bromide | Propantheline bromide | Gastro-Intestinal System | 2 |
|
Propantheline bromide 15mg/5ml oral liquid
0102000Y0AAAIAI
|
Propantheline bromide | Propantheline bromide | Gastro-Intestinal System | 1 |
|
Propantheline bromide 2.5mg/5ml oral solution
0102000Y0AAAYAY
|
Propantheline bromide | Propantheline bromide | Gastro-Intestinal System | No data available |
|
Propantheline bromide 30mg/5ml oral solution
0102000Y0AAAWAW
|
Propantheline bromide | Propantheline bromide | Gastro-Intestinal System | No data available |
|
Propantheline bromide 5mg/5ml oral solution
0102000Y0AAAZAZ
|
Propantheline bromide | Propantheline bromide | Gastro-Intestinal System | No data available |
|
Propantheline bromide 6.25mg/5ml oral solution
0102000Y0AAAXAX
|
Propantheline bromide | Propantheline bromide | Gastro-Intestinal System | No data available |
|
Propantheline bromide 6.4mg/5ml oral solution
0102000Y0AABABA
|
Propantheline bromide | Propantheline bromide | Gastro-Intestinal System | No data available |
|
Propantheline bromide 7.5mg/5ml oral liquid
0102000Y0AABBBB
|
Propantheline bromide | Propantheline bromide | Gastro-Intestinal System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.